On November 19, 2025, Eli Lilly (LLY) closed at $1049.60 (+1.90%), continuing its rapid ascent above the $1,000 mark. This surge is fueled by the ongoing success of its GLP-1 drugs, Zepbound and Mounjaro, and robust financial results, leading to intense speculation about a possible stock split. Market analysts and investors are closely watching for any official announcement, as a split could increase liquidity and retail participation. The company's strong fundamentals and blockbuster drug sales remain the primary drivers, while the stock split rumors have added further momentum to recent gains.